Abstract
Treatment with a beta-adrenergic blocker (beta-blocker) in hypertension is associated with increased plasma atrial natriuretic peptide (ANP) levels despite a decrease in cardiac overload. The mechanism and pathophysiological significance of the phenomenon remain unclear. To clarify the role of the ANP system in the antihypertensive effects of the beta-blocker, we investigated the effects of carvedilol (30 mg/kg x day, orally, for 4 weeks) on the ANP system in stroke-prone spontaneously hypertensive rats (SHR-SP/Izm). Plasma ANP levels showed a significant increase despite a significant decrease in blood pressure and heart rate in the carvedilol group. Although ANP messenger RNA levels in the heart did not change, messenger RNA levels of the natriuretic peptide-C (NP-C) receptor as a clearance receptor showed a significant decrease in both the aorta and lung in the carvedilol group. NP-C receptor densities were also significantly decreased in the lung in this group. The biological half-life of exogenous ANP in circulating blood was prolonged in the carvedilol group compared with that in the control group. Administration of the ANP receptor antagonist, HS-142-1, resulted in a greater increase in systolic blood pressure in the car...Continue Reading
Citations
Feb 2, 2008·Surgery Today·Kanetaka MaeshiroKazuo Shirouzu
Jul 25, 2003·European Journal of Drug Metabolism and Pharmacokinetics·P KotridisC L Papadopoulos
Sep 25, 2003·European Journal of Drug Metabolism and Pharmacokinetics·C L Papadopoulos, B A Kokkas
Jun 11, 2016·Molecular and Cellular Endocrinology·Senthamizharasi ManivasagamElangovan Vellaichamy
Mar 8, 2002·British Journal of Anaesthesia·M ZauggD R Spahn
Apr 5, 2008·Angiology·Manolis S KallistratosDennis V Cokkinos
Sep 26, 2003·Journal of Cardiovascular Pharmacology·Anton H van den MeirackerFrans Boomsma
Sep 13, 2002·Microscopy Research and Technique·Magnus Hansson
Feb 27, 1999·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·T C ChuD E Potter
Feb 17, 1999·Circulation·A M RichardsT G Yandle
Nov 6, 2002·Circulation·Roberto LatiniUNKNOWN Valsartan Heart Failure Trial Investigators
Nov 4, 2000·Current Hypertension Reports·B J PearsonJ D Spence
May 3, 2006·Clinical Cardiology·Seon Woon KimEun-Seok Jeon
May 9, 2002·European Journal of Drug Metabolism and Pharmacokinetics·B KokkasC L Papadopoulos
Apr 1, 2010·Basic & Clinical Pharmacology & Toxicology·Erja MustonenJaana Rysä
Jul 23, 2005·Microscopy Research and Technique·Magnus Hansson
Jun 15, 2007·Annals of Medicine·Richard W TroughtonM Gary Nicholls
Aug 3, 2001·Cardiovascular Drug Reviews·J ChengI Kodama